Ines Erkizia-Santamaría

Ines Erkizia-Santamaría

Auto-generated profile, based on publicly available information

Ines Erkizia-Santamaría

Department of Pharmacology, University of the Basque Country EHU, Leioa, Bizkaia, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
IEInes Erkizia-Santamaría
Ines Erkizia-Santamaría
IHIgor Horrillo
Igor Horrillo
NMNerea Martínez-Álvarez
Nerea Martínez-Álvarez
DPDaniel Pérez-Martínez
Daniel Pérez-Martínez
GRGuadalupe Rivero
Guadalupe Rivero
JOJorge E. Ortega
Jorge E. Ortega
Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical trials. However, its antidepressant mechanism of action is still not well understood. The aim of the present study was to evaluate the therapeutic potential of psilocybin in ameliorating the adverse behavioural and neurochemical consequences of chronic stress. To this end, a chronic unpredictable mild stress (CUMS) animal model was used, and psilocybin treatment was administered (two doses of 1 mg/kg, i.p., administered 7 days apart). Psilocybin reversed impairments in anhedonia and behavioural despair dimensions of depressive phenotype but not in apathy-related behaviour. Psilocybin administration was also able to exert an anxiolytic-like effect on treated animals. Physiological alterations caused by stress, indicative of a hyperactive hypothalamic-pituitary-adrenal axis (HPA), were not reversed by psilocybin. When neuroplasticity-related proteins were assessed in cerebral cortex, brain-derived neurotrophic factor (BDNF) was found to be decreased in stressed animals, and treatment did not reverse such impairment. Psilocybin administration increased the expression and function of serotonin-2A-receptor (5HT2AR) in brain cortex of control and CUMS groups. Furthermore, psilocybin treatment caused a selective increase in the expression of glucocorticoid-receptor (GR) in brain cortex of CUMS mice. In conclusion, psilocybin was able to rescue impairments in the depressive phenotype, and to induce anxiolytic-like effects. Furthermore, an enhancement in sensitivity to psilocybin-induced HTR was observed following a booster dose. Altogether, this work provides new knowledge on the putative benefit/risk actions of psilocybin and contributes to the understanding of the therapeutic mechanism of action of psychedelics.

9 April 2026 in Neurobiology of Stress
Verified
Journal Article
Open access
IEInes Erkizia-Santamaría
Ines Erkizia-Santamaría
LFLuna Fernández
Luna Fernández
IHIgor Horrillo
Igor Horrillo
JMJ Javier Meana
J Javier Meana
JOJorge E. Ortega
Jorge E. Ortega
The chronic unpredictable mild stress (CUMS) paradigm is one of the most widely used preclinical models to investigate the role of stress in the neurobiology of depression and to evaluate potential antidepressant therapies, owing to its strong translational relevance. However, despite its extensive use, substantial discrepancies and concerns regarding the reproducibility of CUMS outcomes persist in the literature, with many studies reporting inconsistent or unreliable results. In the present comparative study, we implemented several CUMS protocols in mice that differed in the intensity and duration of stress exposure, and systematically evaluated the resulting pathophysiological and behavioural alterations associated with depressive- and anxiety-like phenotypes. We found that progressive escalation in stress intensity and frequency, as well as prolonged exposure, induced increasingly robust disease-related behavioural and physiological changes, including depression- and anxiety-like behaviours, adrenal hypertrophy, and reduced body weight gain. Moreover, social isolation emerged as a major contributing factor exacerbating stress-induced deficits. Altogether, the data suggest that a multidimensional assessment of behavioural impairments is necessary to accurately interpret the physiological changes that are indicative of a hyperactive hypothalamic-pituitary-adrenal (HPA) axis. Differences in individual stress susceptibility, stressor intensity, frequency, and housing conditions are key determinants of CUMS outcomes. Therefore, precise, detailed, and transparent reporting of protocol parameters is critical to enhance reproducibility and enable meaningful comparisons across studies.

30 December 2020 in Osagaiz: osasun-zientzien aldizkaria
Verified
Journal Article
Closed access
PDF file
IEInes Erkizia-Santamaria
Ines Erkizia-Santamaria
JOJorge E. Ortega
Jorge E. Ortega
IHIgor Horrillo
Igor Horrillo
Depresioa gaixotasun psikiatriko ohikoenen artean dago, eta haren intzidentziaren gorakada etengabea da. Depresioaren jatorria eta mekanismo etiologikoak azaltzen dituzten hainbat teoria garatu diren arren, gaixotasunaren oinarri neurobiologikoaren alderdi asko ezezagunak dira oraindik. Hipotesi esanguratsuenak depresioaren teoria monoaminergikoa, neurotrofikoa eta neuroinflamatorioa dira, eta horien eta beste batzuen jatorria, ebidentziak eta xehetasunak aditzera ematen dira berrikuspen honetan. Iraganean depresioa tratatzeko farmakoen aurkikuntza zorizkoa izan da, eta haien ekintza-mekanismoen ikerketak gaixotasunean ageri diren nahasmendu neurobiologikoei buruzko ezagutza eman digu. Azken hamarkadetan, aldiz, paradigma aldatu da, eta tratamendu berriak depresioaren etiopatogeniaren ituetan oinarritzen hasi dira. Patologiaren tratamendu farmakologikoaren oinarrian antidepresibo klasikoak daude. Duela hamarkada ugari aurkitu ziren, eta geroztik erabili dira: monoaminooxidasaren inhibitzaileak, antidepresibo triziklikoak eta monoaminen birxurgapenaren inhibitzaileak. Trazodona eta mirtazapina antidepresiboak, profil farmakodinamiko konplexuagokoak, urte batzuk geroago garatu ziren. Farmako talde horien eragin desiragaitz ohikoak ekiditeko eta tratamenduaren eraginkortasuna hobetzeko xedez ekintza-mekanismo alternatiboak esploratu dira, eta ikerketa horietatik sortu dira, esate baterako, agomelatina, tianeptina eta bortioxetina. Horien eraginkortasuna eta erabilera oso mugatuak dira, dena den. Ketamina, aldiz, denbora laburrean depresioaren tratamenduaren iraultza abian jarri duen substantzia izan da, sintomen hobekuntza nabarmena eta azkarra erakutsi duelako entsegu anitzetan, segurtasun eta tolerantzia egokiarekin batera. Azkenik, nabarmentzekoak dira substantzia haluzinogenoak, depresioaren eta beste gaixotasun psikiatrikoen tratamendurako erakutsi duten potentzial izugarriari esker. Depresioari dagokionez, psilozibina da psikodelikoen artean azpimarragarriena: paziente deprimituen hobekuntza azkarra eta iraunkorra eragiten badu ere, haren mekanismo antidepresiboak ezezagunak dira, eta horiek argitzeko entseguak ikerketaren gailurrean daude egun.

10 May 2023
Verified
Conference Paper
Closed access
JCJorge Emilio Ortega Calvo
Jorge Emilio Ortega Calvo
JMJ Javier Meana
J Javier Meana
IFIgor Horrillo Furundarena
Igor Horrillo Furundarena
ISInes Erkizia Santamaria
Ines Erkizia Santamaria
NÁNerea Martinez Álvarez
Nerea Martinez Álvarez
Psilozibinaren administrazio akutuaren eraginen ebaluazioa garun kortexean serotonina, noradrenalina eta dopamina mailak neurtuz: garun-mikrodialisiaren bidez burututako ikerlana esna dauden saguetan produkzioaren informazio-fitxa

8 June 2021
Verified
Conference Paper
Closed access
ISInes Erkizia Santamaria
Ines Erkizia Santamaria
JCJose Enrique Ortega Conejero
Jose Enrique Ortega Conejero
IFIgor Horrillo Furundarena
Igor Horrillo Furundarena

2 December 2025 in bioRxiv
Verified
Preprint
Open access
IEInes Erkizia-Santamaría
Ines Erkizia-Santamaría
LFLuna Fernández
Luna Fernández
IHIgor Horrillo
Igor Horrillo
JMJ Javier Meana
J Javier Meana
JOJorge E. Ortega
Jorge E. Ortega
The chronic unpredictable mild stress (CUMS) paradigm is one of the most widely used preclinical models to investigate the role of stress in the neurobiology of depression and to evaluate potential antidepressant therapies, owing to its strong translational relevance. However, despite its extensive use, substantial discrepancies and concerns regarding the reproducibility of CUMS outcomes persist in the literature, with many studies reporting inconsistent or unreliable results. In the present comparative study, we implemented several CUMS protocols in mice that differed in the intensity and duration of stress exposure, and systematically evaluated the resulting pathophysiological and behavioural alterations associated with depressive- and anxiety-like phenotypes. We found that progressive escalation in stress intensity and frequency, as well as prolonged exposure, induced increasingly robust disease-related behavioural and physiological changes, including depression- and anxiety-like behaviours, adrenal hypertrophy, and reduced body weight gain.. Moreover, social isolation emerged as a major contributing factor exacerbating stress-induced deficits. Altogether, data suggest that a multidimensional assessment of the behavioural impairments is critical to reinforce the physiological changes indicative of a hyperactive hypothalamic-pituitary-adrenal axis (HPA). Differences in individual stress susceptibility, stressor intensity, frequency, and housing conditions are key determinants of CUMS outcomes. Therefore, precise, detailed, and transparent reporting of protocol parameters is critical to enhance reproducibility and enable meaningful comparisons across studies.